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3-Deoxyadenosine, also known as cordycepin, is a known
polyadenylation inhibitor with a large spectrum of biological
activities, including anti-proliferative, pro-apoptotic and anti-
inflammatory effects. In this study we confirm that cordycepin
reduces the length of poly(A) tails, with some mRNAs being
much more sensitive than others. The low doses of cordycepin
that cause poly(A) changes also reduce the proliferation of
NIH3T3 fibroblasts. At higher doses of the drug we observed
inhibition of cell attachment and a reduction of focal adhesions.
Furthermore, we observed a strong inhibition of total protein
synthesis that correlateswith an inhibition ofmammalian target
of rapamycin (mTOR) signaling, as observed by reductions in
Akt kinase and 4E-binding protein (4EBP) phosphorylation. In
4EBP knock-out cells, the effect of cordycepin on translation is
strongly reduced, confirming the role of this modification. In
addition, the AMP-activated kinase (AMPK) was shown to be
activated. Inhibition of AMPKprevented translation repression
by cordycepin and abolished 4EBP1 dephosphorylation, indi-
cating that the effect of cordycepin onmTOR signaling and pro-
tein synthesis is mediated by AMPK activation. We conclude
that many of the reported biological effects of cordycepin are
likely to be due to its effects on mTOR and AMPK signaling.
Cordycepin (3-deoxyadenosine) is found in the parasitic
fungus Cordyceps miltaris and has been proposed as the active
component of traditionalmedication that is reputed to alleviate
a large variety of ailments (1–3). It has been reported to have
numerous biological activities, including the inhibition of cell
proliferation (4–6), induction of apoptosis (7–10), inhibition of
platelet aggregation (11), inhibition of cell migration and inva-
siveness (4, 12), and inhibition of inflammation (13). In mice,
cordycepin can reduce tumor formation in a model of metasta-
sis (12) and has therefore been proposed as a cancer drug. The
effect of cordycepin on RNApolymerases has been shown to be
relatively minor. In contrast, cordycepin strongly inhibits
mRNA polyadenylation, presumably by causing chain termina-
tion after it has been incorporated as cordycepin triphosphate
(14). At high doses cordycepin inhibits incorporation of labeled
uridine into mRNA, but not into its precursor hnRNA, indicat-
ing that the export, processing, or stability of transcribed
mRNA is inhibited, rather than primary synthesis (15).
In this study, we confirm that cordycepin causes a decrease in
the poly(A) tail size of specificmRNAswith somemRNAsbeing
much more sensitive to cordycepin than others. Low doses of
cordycepin cause a decrease in cell proliferation. At high doses,
however, cordycepin prominently affects cell adhesion and
indirectly reduces protein synthesis to very low levels. It shuts
down a signal transduction pathway, the mTOR5 pathway,
which is known to control proliferation, cell adhesion, andprotein
synthesis (16–18). In contrast to rapamycin, cordycepin inhibits
the activities of both the mTORC1 and the mTORC2 complexes,
affecting the activity of the protein kinase Akt. Adenosine is a
cordycepin antagonist, and inhibitors of adenosine import and
phosphorylation prevent the effect of cordycepin on protein syn-
thesis, indicating that this drug is acting intracellularly and needs
to be converted to cordycepin monophosphate. Cordycepin was
also shown to function as an activator of the AMPK pathway. An
inhibitor of AMPK blocked cordycepin-mediated inhibition of
translation and Akt dephosphorylation, indicating the effects of
cordycepinon translationandmTORsignalingaremediatedby its
activation of AMPK. These effects of cordycepin explain most of
the observations reported in tissue culture experiments and pro-
vide a mechanistic explanation for the action of this agent as an
anti-proliferative and anti-inflammatory drug.
EXPERIMENTAL PROCEDURES
Reagents—Cordycepin, cordycepin triphosphate, LY294,002,
rapamycin, nitrobenzylthioinosine and iodotubericidin were
purchased from Sigma and dissolved in DMSO at 1000-fold
concentrated stock to obtain the indicated final concentrations.
Compound C (6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyri-
din-4-ylpyrazolo[1,5-a]pyrimidine) was purchased from Sigma
and dissolved in DMSO at 5 mM.
RNA Isolation and Poly(A) Tests—RNA was isolated accord-
ing to Chomczynski and Sacchi (19). RNA ligation-mediated
poly(A) tests were performed as described by Rassa et al. (20)
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andKlenowpriming poly(A) tests as described byDi Penta et al.
(21). Oligonucleotides were purchased from Invitrogen. The
primers used for Rps4x and Actg1 have been reported previ-
ously (22). Other primer sequences were as follows: Cdkn1a-1,
GTCTGGACTGTCTACCCTTA; Cdkn1a-2, CAGGACACT-
GAGCAATGGCT; Hif1a, CCCACCCTGTTGGTATAAAG;
Atf4, GCGAGTGTAAGGAGCTAGAA; and Rpl28, GCCAC-
TTCTTATGTG.
Tissue Culture, Protein Synthesis, Polysome Profiles, and Cell
Adhesion Assays—NIH3T3 cells were cultured in Dulbecco’s
modified Eagle’s medium (Sigma) with 10% fetal bovine serum,
4.5 g/liter glucose and passaged every 2–3 days. For each exper-
iment, the cells were plated at a density of 20,000 cells/cm2 the
day before use.
For determination of protein synthesis rates inNIH3T3 cells,
cells were plated in 4 replicates in 24-well plates at 25,000 cells/
well the day before use. After the indicated treatments, the
medium was removed, the wells were washed twice with PBS,
and 5–15 Ci/ml Tran35S label (MP biologicals) was added in
cysteine- and methionine-free Dulbecco’s modified Eagle’s
medium. The cells were incubated at 37 °C for 10–15 min, the
medium was removed, and the plate was placed on ice. After
two PBS washes, the cells were extracted with 50 l of passive
lysis buffer (Promega) per well. Incorporation wasmeasured by
trichloroacetic acid precipitation on Whatman 3MM paper,
and protein content was determined using Coomassie Reagent
(Thermo/Pierce). The incorporation was corrected for the pro-
tein content, and the average incorporation of the control was
set at 100%. An error bar representing one standard deviation is
shown in each graph.
For polysome profiling, cells were grown as described above.
They were treated with 100 g/ml cycloheximide for 15 min at
37 °C, washed with ice-cold PBS, scraped, and pooled on ice.
The cell pellet was lysed in 1% Triton X-100, 300 mM NaCl, 15
mM MgCl2, 100 g/ml cycloheximide, 1 mg/ml heparin,15 mM
Tris/HCl, pH 7.5, and centrifuged. The supernatant was loaded
on a 10–60% sucrose gradient in the same buffer without Tri-
ton and centrifuged at 38,000  g for 2 h. 1-ml fractions were
collected, and RNA was isolated and transferred to a Northern
blot. The methylene blue stain of such a blot is shown.
To characterize cell spreading, cells were cultured as
described above, detached with trypsin/EDTA, resuspended in
medium with serum, and washed once with serum-free
medium (Dulbecco’s modified Eagle’s medium with 10 mM
HEPES, pH7), before being resuspended in serum-freemedium
at 1 million cells/ml. The resuspended cells were incubated
with shaking at 37 °C for 1 h to dissolve all focal adhesions,
diluted in serum-containing medium, and plated on glass cov-
erslips in the presence of the indicated drugs for 5 h. Fixing and
staining with phalloidin and Hoechst was as described below.
For immunohistochemistry and phalloidin staining, cells
were plated on glass coverslips in the presence of serum. After
treatment, cells were fixedwith 4%paraformaldehyde. Vinculin
antibody was applied at 1:200 in 3% bovine serum albumin in
PBS. The secondary antibodywas anti-mouse-coupled toAlexa
546 (Molecular Probes), also at 1:200 in 3% bovine serum albu-
min in PBS. Phalloidin stains were performed with fluorescein
isothiocyanate- or TRITC-coupled phalloidin from Sigma at
2.5 g/ml in PBS. Hoechst (Sigma) stains were performed at 5
g/ml in PBS. Imagingwas performed on a Zeiss LSM510Meta
confocal microscope, and the images were processed using the
manufacturer’s software.
Mouse embryonic fibroblasts were cultured as for NIH3T3
cells. Knock-in mutant cells in which Ser51 of eIF2 was
replaced by Ala (S51A cells) and their matched controls were a
gift from Dr. R. J. Kaufman (23). Cells from mice with disrup-
tions in the genes for 4EBP1 and 4EBP2 (double knockouts) and
their matched controls were a gift from Dr. N. Sonenberg (24).
Protein synthesis was determined by incubation of the cells in
complete medium containing [35S]methionine (7 Ci/ml) for
1 h. The cells were washed with PBS, then dissolved in 0.3 M
NaOH, and protein was precipitated with 10% (w/v) trichloro-
acetic acid and filtered through glass fiber paper. Protein con-
tent was determined, and incorporation of radioactivity was
analyzed as described above for NIH3T3 cells.
InVitroTranslation—The sensitivity of in vitro translation to
cordycepin and cordycepin triphosphate was determined in
reticulocyte lysate that had not been treated with nuclease,
essentially as described previously (25). The nucleosides and
nucleotides indicated were added to a final concentration of
200 M. No ATP was added to the reaction unless otherwise
indicated.
Antibodies and Western and Northern Blots—For Western
blots, cells cultured as described above were scraped in cold
PBS on ice and collected by centrifugation. After washes with
cold PBS, the cell pellet was lysed in radioimmune precipitation
assay buffer (PBS, 0.1% SDS, 0.5% Igepal, 0.5% sodium deoxy-
cholate), and the protein concentration was determined. Equal
amounts of protein,25–40g/sample, were analyzed by SDS
gel electrophoresis and blotting on Hybond-C membranes
(Amersham Biosciences). Antibodies were used for Western
blotting according to the manufacturers’ recommendations.
Vinculin and -actin antibodies were purchased from Sigma.
Antibodies against total and phosphorylated eIF2 (Ser51),
total and phosphorylated Akt1 (Ser473), phospho and total
AMPK1 (Ser108), total and phosphorylated Acetyl-CoA Car-
boxylase (Ser79), and total and phosphorylated 4EBP1
(Thr37/46) were purchased from Cell Signaling Technology.
Northern blots for -actin and Cdkn1a were performed as
described previously (22).
RESULTS
To assess if cordycepin does indeed influence the poly(A) tail
length of individual mRNAs in mammalian cells, we incubated
NIH3T3 fibroblasts with 10, 50, or 200 M of the drug for 2 h
and examined the poly(A) tails of a set of mRNAs for which we
had RNA ligation based polyadenylation test assays available.
As can been seen in Fig. 1A, the mRNAs encoding Hif1a and
Atf4 showed reduced polyadenylation already at the 10 M
dose. Actg1 (-actin), Rps4x, andRpl28mRNAsweremuch less
sensitive to cordycepin. To investigate the effect of cordycepin
on the poly(A) tails of different mRNAs in more detail, we used
a Klenow priming-based polyadenylation test assay on RNA
from cells treated for different times with 50 M cordycepin
(Fig. 1B). Again different mRNAs showed different sensitivities
to cordycepin, with Hif1a, Cdkn1a, and Atf4 being sensitive,
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making it unlikely that it is an artifact of the type of polyad-
enylation assay used. We also developed a duplicate polyad-
enylation assay, using twodifferentmRNA-specific primers, for
the Cdkn1a mRNA and found very similar effects for both
assays. By quantifying the gels and normalizing the data to have
equal maximum signals, it became apparent that the effect of
cordycepin treatment was greatest mRNAs that had a large
spread of poly(A) tail lengths.mRNAswith a very small fraction
of poly(A) tails above the median length, such as the ribosomal
protein mRNAs, were not significantly affected. For the
mRNAs tested, the effects of the transcription inhibitor actino-
mycinD on poly(A) tail lengthwere similar to those of cordyce-
pin (results not shown), indicating that the long poly(A) tails are
dependent on ongoing transcription and are therefore likely to
represent newly transcribed mRNAs that receive long poly(A)
tails in the nucleus. These data show that the poly(A) tails of
somemRNAs aremore sensitive to cordycepin than others and
that low doses of cordycepin are sufficient to achieve these
effects.
To investigate if the effect of cordycepin on the poly(A) tail of
Cdkn1a had consequences for the abundance of thismRNA,we
performed Northern blots. As can be seen in Fig. 1C, the levels
of Cdkn1a mRNA had nearly halved in 45 min compared with
the -actin mRNA levels, demonstrating that cordycepin can
strongly affect the abundance of certain mRNAs.
We next investigated whether low doses of cordycepin affect
cell proliferation in our system. NIH3T3 fibroblasts were
seeded at 106 cells per plate and incubated with 5 or 10 M
cordycepin for 72 h, with a medium change at 24 and 48 h.
Normally, the cells divide twice under these conditions. As can
be seen in Fig. 1D, cell numbers weremarkedly decreased in the
presence of cordycepin, indicating that the drug inhibits cell
division. Fluorescence-activated cell sorting analysis indicated
that therewas no increase in apoptotic cells (results not shown).
When we were incubating our cells with cordycepin for the
polyadenylation assays, we noticed that the higher doses of
cordycepin caused changes in cell shape. To examine these
changes in more detail, we performed immunohistochemistry
with the focal adhesionmarker vinculin and a stain for filamen-
tous actin (phalloidin). As can be seen in Fig. 2A, 50 and 200M
cordycepin treatment for 3 h caused the cells to withdraw their
edges toward the nucleus and only retain thin protrusions. No
such effect was observed with the translation inhibitor cyclo-
heximide over the same time period. When the cells were
examined at higher magnification the actin cytoskeleton
appeared disorganized, and focal adhesions were almost absent
in cordycepin-treated cells (Fig. 2B).
To study the effect of cordycepin on adhesion further, we
examined the influence of cordycepin on cell adhesion and
spreading after detachment, when focal adhesions are formed
de novo.We detachedNIH3T3 cells with trypsin, washed them,
and kept them in suspension for 1 h to disassemble all pre-
existing focal adhesions. Cells are completely rounded after this
procedure. We then plated them on coverslips in the presence
of cordycepin for 5 h, which is the time the cells normally need
to spread fully, and stained the cells with fluorescent phalloidin
(for filamentous actin). The morphology of untreated and
cordycepin-treated cells was very different with the phalloidin
stain, with a high level of disorganisation and a lack of spreading
in the treated cells (Fig. 3A).We counted the number of incom-
pletely spread cells as those that do not reach a diameter of 25
m or more and expressed it as a percentage of the total num-
ber of cells. As can be seen in Fig. 3B, 10 M cordycepin had no
detectable effect on cell spreading, whereas 50 and especially
200 M caused an increase in the number of incompletely
spread cells. To investigate if this effect is due to cordycepin
blocking transcription or translation of a crucial factor, we
repeated this experiment with the transcription inhibitor acti-
nomycin D and the translation inhibitor cycloheximide. As can
be seen in Fig. 3C, actinomycin D had no effect on cell spread-
ing, whereas cycloheximide had a moderate effect. This indi-
cates that cordycepin has effects on cell spreading that are not
mediated through inhibition of transcription.
To determine the effect of cordycepin on cellular translation,
we measured radioactive amino acid incorporation for 10 min
after treatment with cordycepin, adenosine, or actinomycin D
for 2 h.As can be seen in Fig. 4A, cordycepin at 200M inhibited
translation by up to 95%,whereas adenosine and actinomycinD
hadno effect.We then examined the effect of cordycepin on the
association of mRNAs with ribosomes using high salt sucrose
gradient centrifugation. In these gradients, ribosomes that are
not engaged in translation dissociate into 40 and 60 S subunits
(26). Fig. 4B shows the polyribosome profile of untreated and
treated cells. In treated cells there was a large increase in the
free ribosomes (40 and 60 S) and a decrease in the polyribosome
levels, indicating that there is repression of translation by
cordycepin at the level of initiation. Fig. 4C shows the dose
response of the effect of cordycepin on translation. From 50M
onward there is a significant effect on translation, with smaller
effects at 10 and 20 M. This is confirmed in the time course in
Fig. 4D, which also demonstrates that themaximal repression is
reached after 1 h of cordycepin incubation. A similar dose
response was seen in HeLa cells (Fig. 4E). These data demon-
strate that cordycepin is a strong inhibitor of translation in
mammalian cells.
To investigate the possibility that cordycepin is inhibiting
translation directly, we added 200 M adenosine, cordycepin,
ATP, or cordycepin triphosphate to a rabbit reticulocyte in
FIGURE1.Cordycepinaffectspoly(A) tail lengthandcellproliferationat lowconcentrations.A, RNA ligationpoly(A) testsonRNA fromNIH3T3cells treated
with different doses of cordycepin. RNase H Oligo(dT) indicates RNA from untreated cells digested with RNase H and oligo(dT) to remove the poly(A) tail as
a control. The GenBankTM gene name abbreviations indicate which mRNAs were tested: Hif1a (hypoxia-inducible factor 1), Cdkn1a (p21/Waf/Cip), Atf4
(activating transcription factor 4), Actg1 (gamma1 actin), Rps4X (X-linked ribosomal protein S4), and Rpl28 (ribosomal protein L28). B, Klenow priming poly(A)
tests on a time course of cordycepin treatment. On the right side the panels shows the distribution of the intensity in each lane as a percentage of themaximum
intensity in that lane on the vertical axis and the size of the poly(A) test products in base pairs on the horizontal axis. Black, oligo(dT) RNase A-treated sample;
purple, no treatment; green, 15-min cordycepin; dark blue, 30-min cordycepin; light blue, 45-min cordycepin; and orange, 60-min cordycepin. C, Northern blot
for Cdkn1a and -actin (Act1b) on total RNA isolated from cells treated with 50 M cordycepin for the indicated times. D, cell numbers after 72 h of treatment
with cordycepin (medium refreshed daily, including drug).
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vitro translation system. As can be seen in Fig. 4F, neither
cordycepin nor cordycepin triphosphate inhibited in vitro
translation, indicating that the effect is indirect. Cap analogue,
a dinucleotide known to inhibit translation initiation, didmark-
edly repress in vitro translation.
Cellular protein synthesis rates are predominantly down-
regulated by the modification of translation initiation factors
and their interacting proteins, especially via the phosphoryla-
tion of eIF2 and the dephosphory-
lation of 4EBP (18). We therefore
performed Western blots for these
proteins and their phosphorylated
forms on cells treated with different
doses of cordycepin for 2 h. As can
be seen in Fig. 5A, an increase in
eIF2 phosphorylation was detecta-
ble at 20 M, whereas a decrease in
4EBP1 phosphorylation was first
detected with 50 M cordycepin.
Because 4EBP phosphorylation is
mediated by mTOR, we also inves-
tigated the mTOR-mediated phos-
phorylation of Akt1. Akt1 is a kinase
that is involved in cell adhesion and
proliferation, and its phosphory-
lation by the mTORC2 complex is
known to be upstream of activation
ofmTORC1, thecomplex thatphos-
phorylates 4EBP, as summarized in
Fig. 8 (27). Akt1 phosphorylation
was very strongly inhibited by 50M
cordycepin, and the levels of the
protein kinase were also reduced,
indicating that the block of mTOR
signaling is at the level of Akt or
upstream. Time courses of these
changes indicated that Akt and
4EBP1 were dephosphorylated
within 30 min of treatment of cells
with 200 M cordycepin (Fig. 5B),
coinciding with the decrease in
overall protein synthesis (Fig. 4D),
whereas the increased phosphoryla-
tion of eIF2 only occurred at later
times.
Rapamycin can inhibit the activ-
ity of the mTORC1 complex and
prevent the phosphorylation of
4EBPs in cells stimulated with
growth factors (28). However, as
shown in Fig. 5C, a 2-h treatment
with even quite high doses of rapa-
mycin did not reduce translational
activity in our cells, even though it
did somewhat reduce 4EBP1 and
Akt1 phosphorylation (Fig. 5D). In
contrast, LY294,002, an inhibitor of
the growth signal transducer phos-
phatidylinositol 3-kinase, did reduce translation and abolished
4EBP1 and Akt1 phosphorylation (Figs. 5C, 5D, and 8). These
data are consistentwith the effect of cordycepin beingmediated
by a severe reduction in Akt/mTORC2 signaling.
To determine the relative importance of 4EBP dephosphor-
ylation and eIF2 phosphorylation for the inhibition of protein
synthesis by cordycepin, we employed mutant mouse embryo
fibroblasts in which either Ser51 of eIF2 was replaced by Ala
FIGURE 2. Cordycepin affects the actin cytoskeleton and dissolves focal adhesions. NIH3T3 cells were
plated on coverslips the day before and treated for 3 h with cordycepin (50 or 200 M) or cycloheximide (100
g/ml). The cells were fixed and stained with an antibody against vinculin (red) to detect focal adhesions and
phalloidin (green) to detect filamentous actin. A, microscopy of control cells treated with the indicated drugs
with the stains imaged separately as well as merged. B, higher magnification merged image with the same
stains for control and cordycepin-treated cells. Arrows indicate focal adhesions in the untreated cell.
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(S51A cells) (23) or in which the genes for 4EBP1 and 4EBP2
were disrupted (24). As can be seen in Fig. 6, both mutant cell
lines showed some resistance to cordycepin, compared with
their correspondingwild-type controls. The reduced sensitivity
to the inhibitor was particularly marked in the 4EBP double
knock-out cells, suggesting that 4EBP dephosphorylation is an
important mechanism by which cordycepin inhibits
translation.
We sought to further clarify the mechanism by which
cordycepin inhibits protein synthesis. To confirm that cordyce-
pin is acting as an adenosine antagonist, we added an equal
amount of adenosine to the cell cultures. As can be seen in Fig.
7A, this completely abolished the repression of protein synthe-
sis. This shows that cordycepin is interfering with a normal
function of adenosine or its metabolites. To exclude that
cordycepin is acting extracellularly, for instance by binding
to adenosine receptors, we preincubated the cells with the
adenosine import inhibitor nitrobenzylthioinosine. As
shown in Fig. 7B, nitrobenzylthioinosine completely blocked
the effect of cordycepin on protein synthesis. Similarly, iodo-
tubericidin, an inhibitor of adenosine phosphorylation, also
blocked the inhibition of protein synthesis. These data show
that cordycepin acts intracellularly and as a nucleotide,
rather than a nucleoside.
AMPK is an energy and nutrient sensor that is normally acti-
vated when the ratio of AMP to ATP increases, and it is an
important negative regulator of
mTOR signaling and protein syn-
thesis (29, 30). We therefore
checked if AMPK was activated by
cordycepin treatment. As can be
seen in Fig. 7C, phosphorylation of
AMPK on its autophosphorylation
site in the  subunit (Ser108)
increased within 30 min of treat-
ment with cordycepin (31). Effects
on AMPK activity coincided with
the dephosphorylation of Akt1 and
4EBP1. To test if the activation of
AMPK is required for the inhibition
of protein synthesis by cordycepin,
we added the AMPK inhibitor
Compound C 15 min before a 1-h
treatment with cordycepin and
determined the effect on protein
synthesis and 4EBP1 phosphoryla-
tion.As can be seen in Fig. 7D, Com-
pound C completely cancelled the
effect of cordycepin on protein syn-
thesis. In addition, Compound C
repressed the phosphorylation of
AMPK and enhanced phosphory-
lation of Akt1 (Fig. 7E). Compound
C also prevented the cordycepin-in-
duced dephosphorylation of 4EBP1.
These data indicate that cordycepin
is primarily mediating its effect on
protein synthesis through AMPK-
mediated inhibition of mTOR signaling.
DISCUSSION
In this study we have shown that at low doses cordycepin
affects the poly(A) tails of specific mRNAs, and this correlates
with a reduction in cell proliferation. Surprisingly, at higher
doses cordycepin also inhibits cell adhesion and virtually abol-
ishes protein synthesis, probably through its effects on Akt and
4EBP phosphorylation. The most upstream target of cordyce-
pin at higher doses appears to be AMPK, which it activates,
leading to the observed reduction in mTOR signaling. There-
fore the twomain effects of cordycepin appear to be the inhibi-
tion of polyadenylation at low doses and the activation of
AMPK at higher doses.
We demonstrate that cordycepin reduces the poly(A) tail
length of a subset ofmRNAs (Fig. 1). ThesemRNAs are likely to
represent unstable mRNAs that need constant co-transcrip-
tional polyadenylation to maintain their levels. Conversely,
othermRNAs are resistant to both cordycepin and actinomycin
D, suggesting that thesemRNAs do not require transcription to
maintain their poly(A) tail length and are protected from dead-
enylation and degradation in the cytoplasm. Even low doses of
cordycepin have effects on the polyadenylation of sensitive
mRNAs, and for one such mRNA (Cdkn1a) a rapid drop in
mRNA levels in response to cordycepin was observed. This
indicates that cordycepin acts at least in part by reducing the
FIGURE 3. Cordycepin inhibits cell spreading. NIH3T3 cells were detached, suspended for 1 h in serum-free
medium, and allowed to re-attach to coverslips with serum for 5 h in the presence or absence of cordycepin,
cycloheximide, or actinomycin D at the concentrations indicated. After fixation, cells were stained with phal-
loidin to visualize the actin cytoskeleton. A, images of typical control and cordycepin-treated cells. B and C,
quantitation of the percentage of unspread cells (largest diameter, 25 m or less) in cells incubated with the
indicated doses of drugs.
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FIGURE 4. Cordycepin inhibits protein synthesis. A, protein synthesis rates of NIH3T3 cells asmeasured by 35S incorporation into protein, corrected for total
protein concentration. Theeffectsof treatmentwith200Mcordycepinor adenosineorwith10g/ml actinomycinD (AcD) are shown.B, polyribosomeprofiles
of control cells and cells treated with cordycepin (200 M) for 2 h. 40S and 60S indicate the dissociated free ribosomal subunit peaks, polysomes indicates
ribosomes translatingmRNA. The inset shows theRNA isolated fromacontrol gradient, proving the identificationof the40Speak.C, dose responseof theeffect
of cordycepin on protein synthesis rates in NIH3T3 cells treated for 2 h. D, time course of the response of protein synthesis rates to three doses of cordycepin.
E, dose response of the effect of cordycepin on protein synthesis rates in HeLa cells treated for 2 h. F, incorporation of radioactive methionine into protein in
vitro in reticulocyte lysate supplemented with cordycepin, adenosine, cordycepin triphosphate (cordyTP), ATP, or cap analogue (m7GpppG) (all at 200 M).
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levels of sensitive mRNAs. This is in
agreement with recent findings in
yeast, where mutations in the
mRNAdegradationmachinery con-
vey resistance to cordycepin (32).
We have also shown clear effects
of cordycepin on cell adhesion, both
in attached cells and in cells adher-
ing from suspension (Figs. 2 and 3).
These effects appear to be at least
partially independent of protein
synthesis, because the strong trans-
lation inhibitor cycloheximide has
little influence on attached cells and
a much less pronounced effect on
adhering cells. It is therefore likely
that the effect of cordycepin on cell
adhesion is mediated through its
inhibition of Akt, which is a well
known regulator of the actin
cytoskeleton (33, 34).
Partial inhibition of translation
by cordycepin in L5178Y cells and
mouse L-cells was reported over 30
years ago (14, 35). In agreement
with this, we now have also
observed inhibition of protein syn-
thesis in NIH3T3 and HeLa cells
(Fig. 4) and in a human colon carci-
noma cell line (results not shown).
This suggests that protein synthesis
is sensitive to cordycepin in a variety
of cell lines. In contrast to this find-
ing is the report that cordycepin
enhances the translation of riboso-
mal protein mRNAs (36). Riboso-
mal proteins contain a 5 oligonu-
cleotide pyrimidine tract, which
mediates serum-stimulated transla-
tion in a manner dependent on
mTOR, but not on the mTORC1 or
-2 complexes (37). In serum-starved
HeLa cells, cordycepin and actino-
mycinDwere found to stimulate the
polyribosome association of these
mRNAs without influencing gen-
eral polyribosome assembly (36).
We have done experiments with
serum-starved NIH3T3 cells, and
we still see a cordycepin-induced
reduction in translational activity as
determined by amino acid incorpo-
ration (results not shown), but we
have not examined the polyribo-
somes under these conditions.
Intriguingly, we consistently see
that ribosomal proteinmRNAshave
relatively homogeneous poly(A)
FIGURE 5. Cordycepin inhibitsmTOR signaling. A, Western blots of extracts fromNIH3T3 cells treated for 2 h
with increasing doses of cordycepin. Blots were developed as indicatedwith antibodies specific for total eIF2
and its phosphorylated form (Ser51), total 4EBP1 and its phosphorylated forms (Thr37/46), Akt1 and its phos-
phorylated form (Ser473), and -actin (as a loading control). Ratios between phosphorylated and total protein
levels are givenunder theblots,with the ratio for the control set at 1.B,Westernblots of extracts of cells treated
for different time periods with 200M cordycepin. C andD, the effect of themTORC1 inhibitor rapamycin and
the phosphatidylinositol 3-kinase inhibitor LY294,002 on protein synthesis and phosphorylation of proteins.
C, protein synthesis rates of NIH3T3 cells as measured by 35S incorporation into protein, corrected for total
protein concentration. D, Western blots of extracts treated with inhibitors as described above.
FIGURE 6. Protein synthesis in murine embryonic fibroblasts lacking 4EBP expression or containing
non-phosphorylatable eIF2 is resistant to cordycepin. Protein synthesis in MEFs from animals lacking
expression of 4EBP1 and 4EBP2 (double knock-out,DKO) (A) andMEFs from animals with the S51Amutation in
eIF2 (B), and their corresponding wild-type controls, was measured by [35S]methionine incorporation into
protein. The cellswerepre-treatedwith 0, 50, and200Mcordycepin for 1.5 h and then labeled for 1h. Thedata
are corrected for total protein concentration and are shown as the means  S.E. of three replicates for each
treatment.
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FIGURE 7.Cordycepin activates AMPK. A, adenosine blocks cordycepin-mediated repression of protein synthesis. NIH3T3 cells were treatedwith cordycepin
and/or adenosine for 2 h, and protein synthesis rates weremeasured by 35S incorporation, corrected for total protein concentration. B, import and phosphor-
ylationof cordycepinare required for inhibitionofprotein synthesis. Cellswere treatedwithnitrobenzylthioinosine (NBTI, 10M)or iodotubericidin (ITu, 0.1M)
for 15 min before treatment with cordycepin (200 M) for 1 h. Protein synthesis rates were determined as before. C, cordycepin induces AMPK activation.
Western blots are shown for AMPK1 and its autophosphorylation site (Ser108), acetyl-CoA carboxylase and its AMPKphosphorylation site (Ser79) aswell as for
the proteins listed in the legend to Fig. 5. Treatment with cordycepin was for the indicated times and dose. D, protein synthesis in cells pretreated with
Compound C or DMSO for 15 min prior to the addition of 200 M cordycepin and incubation for 1 h. E, cells were treated as in D ,and Western blotting was
performed for the proteins indicated as described above.
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tails that are resistant to cordycepin and actinomycinD (Fig. 1),
which could be related to their translational activity during
drug treatment.
It has also been reported that cordycepin lowers c-Myc
mRNA levels in HeLa cells without affecting the levels of pro-
tein produced (38). c-Myc mRNA contains an internal ribo-
some entry site, which could explain why it is resistant to the
inhibition of cap-dependent translation initiation caused by
4EBP dephosphorylation (39).
The fact that neither cordycepin nor cordycepin triphos-
phate inhibits translation initiation in vitro indicates that it
does not interfere directly with ATP-dependent protein syn-
thesis steps such as the aminoacylation of tRNAs or the scan-
ning of the 5-untranslated region by the 43 S initiation com-
plex. It is therefore very likely that the primary cause of the
translation shutdown is the modification of initiation factors.
The strong inhibition of translation observed with higher doses
of cordycepin coincides with a reduction of the amount of
polyribosomes, indicating that an inhibition of translation ini-
tiation does play a role (Fig. 4B). We show that eIF2 is phos-
phorylated and 4EBP1 is dephosphorylated in cells treated with
high doses of cordycepin. In particular, 4EBP1 dephosphoryla-
tion is simultaneous with the decline in protein synthesis, and
the effect of cordycepin on translation is strongly reduced in
4EBP knock-out cells. These findings indicate that the regula-
tion of the availability of eIF4E, via its sequestration by dephos-
phorylated 4E-binding proteins, is a major contributor to the
translational repressionmediated by cordycepin. Nevertheless,
cells lacking 4EBP1 and 4EBP2 are not completely resistant to
the inhibitor (Fig. 6), suggesting that the phosphorylation of
eIF2 may also play a role in the effects of cordycepin on
translation.
The phosphorylation of an upstream-positive regulator of
mTORC1, Akt, is also inhibited in cordycepin-treated cells. As
depicted in Fig. 8, Akt activation is mediated by the mTORC2
complex, and it therefore indicates that cordycepin interferes
with mTOR signaling upstream of Akt and mTORC2.
In addition to its regulation of 4EBP1, mTOR signaling
increases the activity of the translation elongation factor eEF2
by inactivation of its inhibitory kinase through phosphorylation
by S6 kinase (40). Therefore, inhibition of the mTOR pathways
is expected to lead to inhibition of both initiation and elonga-
tion of translation. This is consistent with the observed poly-
some profile, which still shows some polysome assembly,
despite the severely impaired amino acid incorporation (Fig.
4B). In addition, mTORC1 and Akt have been documented to
affect the activity of at least four other initiation factors (41–
44). The inhibition of the mTOR pathway is therefore very
likely to be the cause of the observed down-regulation of pro-
tein synthesis.
The activation of AMPK by cordycepin appears to be
upstream of the down-regulation of the mTOR pathway by
cordycepin, because Compound C can prevent the effects of
cordycepin onmTOR signaling. A similar mechanism has been
demonstrated for protein synthesis inhibition by the type II
diabetes drug metformin (29). In mouse embryonic fibroblasts,
the repression of translation and mTOR signaling by met-
formin was shown to be dependent on the AMPK target and
mTOR inhibitor Tsc2. In Tsc2 knock-out cells, AMPKwas still
activated by metformin, but no down-regulation of mTOR sig-
nalingwas observed. However, the antagonism betweenAMPK
andAkt appears to be bi-directional, at least in some cases, with
Akt activation repressing AMPK activation and Akt down-reg-
ulation increasing AMPK activity (45). We cannot therefore
completely exclude the possibility that the induction of Akt1
phosphorylation by Compound C is blocking a direct effect of
cordycepin on Akt, with AMPK activation by cordycepin being
a secondary effect of the reduction in Akt signaling.
One possible mechanism for the activation of AMPK by
cordycepin is that cordycepin monophosphate is a stronger
activator of AMPK than AMP. Another possibility is that
cordycepin may activate AMPK is through the induction of a
change in the AMP:ATP ratio. We propose that cordycepin
activates AMPK by an unknown mechanism, and this inhibits
FIGURE 8. Summary of the AMPK and mTOR signaling pathways. Phos-
phatidylinositol 3 kinase (PI3K) is activated when growth factors bind to their
receptors. Phosphatidylinositol bisphosphate (PIP2) is converted by PI3K into
phosphatidylinositol trisphosphate (PIP3). This leads to activation of phos-
phoinositide-dependent protein kinase-1 (PDK1). PDK1 phosphorylates Akt1
to partially activate it and prime it for further activation. Full activation is
dependent on an additional phosphorylation of Akt1by mTORC2, a complex
that includes the kinase, mammalian target of rapamycin (mTOR) and the
regulatory subunit Rictor. Akt1 phosphorylates and activates the mTORC1
complex that contains mTOR and the regulatory subunit Raptor. mTORC1
phosphorylates the translation repressor 4EBP and inactivates it. AMPK is
known to inhibit mTORC1 activation at multiple levels. More detail can be
found in Refs. 55, 58. We propose that cordycepin activates AMPK by an
unknownmechanism and that active AMPK somehow also inhibits mTORC2
activity (interactions shown in red), leading to a double block of the mTOR
signaling pathway.
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mTORC2aswell asmTORC1 activity, leading to a double block
of the mTOR signaling pathway as depicted in Fig. 8.
As a polyadenylation inhibitor, cordycepin has been used as a
tool to investigate the role of cytoplasmic polyadenylation in a
variety of systems (e.g. 46–48). In most cases, the doses
employed are high and therefore likely to activate AMPK and
repress mTOR signaling and total protein synthesis. Fortu-
nately, in these studies due care was taken to include other
methods to verify that cytoplasmic polyadenylation is taking
place. However, we have to conclude that an observation of
effects of cordycepin on a biological process can no longer be
used as an indication of a role of cytoplasmic polyadenylation
without rigorous checks on the effects on the AMPK and
mTOR signaling pathways.
Cordycepin has been under investigation as an anti-prolifer-
ative drug for nearly 50 years (49). However, the instability of
themolecule in the body has been problematic so far, due to the
presence of adenosine deaminases. A combination therapy
with an adenosine deaminase inhibitor as a treatment for TdT-
positive leukemia is currently in Phase I/II clinical trials (Onco-
vista, Inc.). Recently, more stable prodrugs have been synthe-
sized, but their potential therapeutic effects have not yet been
assessed (50). Two aspects of the current study indicate that
cordycepin continues to be an interesting lead compound for
cancer therapy as well as a potentially useful tool to identify
therapeutic targets.
Firstly, at low doses, at which the only detectable effect of
cordycepin is on poly(A) tail length, the target is likely to be one
or more of the mRNAs that have a poly(A) tail with a high
sensitivity to cordycepin. These can now be identified using a
poly(A) fractionation microarray screen (22). These low doses
of cordycepin are likely to be achievable in patients with only
moderate modifications in the drug delivery.
Secondly, the mTOR and AMPK pathways are currently
under intense scrutiny as targets in cancer therapy (16, 51–55).
Other AMPK activators, including metformin, have been
shown to be effective in animal models of cancer (56, 57). As
described above, the effects of cordycepin on translation and
mTORsignaling are similar to those observed formetformin. In
addition, the anti-inflammatory effect of cordycepin can be
explained by its effects onmTOR andAMPK signaling, because
cordycepin-mediated repression of inflammation has been
reported to involve the inhibition of Akt (13). As an inhibitor of
Akt and an activator of AMPK, cordycepin therefore is a can-
didate drug for type II diabetes, a potential anti-inflammatory,
and a putative cancer drug. Perhaps tradition was in the right
after all.
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